The length of time and associated costs involved in the development of important therapeutic medicines can put a serious strain on funding resources. In the case of Cardium Therapeutics and their one-of-a-kind DNA-based angiogenic growth factor therapeutic, Generx, being developed for the treatment of patients with advanced coronary artery disease, rather than depending upon outside direct funding sources, the company recognized that it was vital to have a long-term reliable income strategy. Cardium has chosen to diversify, providing layers of short-term and long-term support for their ongoing research, while building a broad marketplace presence.
• Generx – Generx (alferminogene tadenovec, Ad5FGF-4) is uniquely designed to stimulate the growth of supplemental collateral blood vessels in the heart in order to enhance myocardial blood flow in patients who have insufficient blood flow due to atherosclerotic plaque restricting flow in the coronary arteries that supply the heart. It represents an important contrast to traditional drug therapies, such as nitrates and beta blockers, which only provide transient symptomatic relief of anginal chest pain without addressing the underlying disease. Generx has progressed through four randomized, placebo-controlled clinical studies at over 100 medical centers in the United States and Western Europe.
• Excellagen – The company’s lead commercial product, Excellagen, is a syringe-based, professional-use, pharmaceutically-formulated gel that functions as an acellular biological modulator, designed to accelerate the growth of granulation tissue and to activate the wound healing process. Excellagen is FDA-cleared for the treatment of neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds, and is intended for professional use.
• To Go Brands – In October, 2012, Cardium acquired the assets, business and product portfolio of To Go Brands. To Go Brands develops, markets, and sells a portfolio of products including nutraceutical powder mixes, supplements and chews to support healthy lifestyles. The product line contains 100% natural antioxidant-rich drink mixes with organic ingredients, in convenient stick packs, designed to pour directly into a water bottle, mix packages for home use, and capsule-based dietary supplements.
Cardium is involved in the development of other health related products as well, and plans to continue to review acquisitions of other companies and licenses covering product opportunities and technologies.
For additional information, visit www.CardiumTHX.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
